National Hospitals Network of Japan
Dr Steven Chance, Chief Executive Officer, is invited back to Japan by NHO Neurology Research Group to speak on the role of CDM as a potential clinical tool for the detection of dementia. January 2020
Jan 2020 - Oxford Brain Diagnostics is offically regsitered with Scientist.com. A collaborative platform designed to deliver research projects to Pharma/Biotech sector.
Dr Steven Chance, Chief Executive Officer and Omar Ehsan, Chief Commercial Officer, present results at CTAD 2019 - Diagnostics accuracy of whole brain cortical DTI changes measured in Alzheimer's.
Oxford Brain Diagnostics is proud to become a member of the CPAD Intiative. This consortium works with industry, regulatory authorities, and patient advocacy organizations to advance Drug Development Tools (DDTs) for evaluating drug efficacy and safety, to optimize novel clinical trial designs, and aggregating anonymized patient-level data using CDISC consensus standards to facilitate the regulatory review process.
Osaka Chamber of Commerce and Industry
Dr Steven Chance, Chief Executive Officer, is invited by OCCI to speak at Global Innovation Forum - 10 Oct 2019
Researchers hunt for new dementia detection methods. Oxford Brain Diagnostics cited in FT Dementia supplement. September 2019
Ian Hardingham, Chief Technology Officer is invited to speak and provide his insights into the role of AI in Diagnostics and brain health analyitcs.
Dr Steven Chance, Chief Executive Officer, is invited to speak (11th Sept) on the challenges of Healthy Ageing facing healthcare providers in the next 30 years.
Omar Ehsan, Chief Commercial Officer is invited by SETSQUARED at NHSExpo 2019. Looking forward to seeing the latest viewpoints on National Ageing affecting this global challenge.
Head to Head with Dr Steven Chance at Oxford Brain Diagnostics
Dr Steven Chance & Dr Mario Torso present two key results using CDM technology - classifying FTD with machine learning and Differentiating Taupathies to investigate cortical architecture.
Oxford Brian Diagnostics is selected by Department for International Trade to visit Bio 2019 and showcase their diagnostics tool - Cortical Disarray Measurement.
Oxford Brain Diagnostics moves into the heart of Oxford Town centre. We are now located at Oxford Centre for Innovation.
Dr Steven Chance is invited to speak about research findings in Alzheimer's using cortical disarray measurment and some key applications in industry.